What Researchers Did
The researchers gave hyperbaric oxygen to 20 adults in hospital with a moderate to severe ulcerative colitis flare, on top of intravenous steroids, and tested whether 5 days or 3 days of treatment worked better in those who responded early.
What They Found
In this phase 2B trial of 20 hospitalised ulcerative colitis patients, 55 percent (11 of 20) responded by day 3 of hyperbaric oxygen at 2.4 atmospheres, and stool frequency, rectal bleeding and CRP all fell significantly (p less than 0.01). Day 3 responders were randomised to 5 days or 3 days of treatment, and disease activity dropped more with 5 days (p = 0.03). Only three patients (15 percent) needed infliximab or colectomy, compared with a predicted 80 percent probability of second-line therapy. By 3 months, day 3 responders had no re-hospitalisation or colectomy, versus 66 percent of non-responders (p = 0.002). No treatment-related adverse events were observed.
What This Means for Canadian Patients
For people hospitalised with a severe ulcerative colitis flare, this small early-stage trial tested hyperbaric oxygen added to intravenous steroids. The authors say it appears effective for improving response to steroids, with 5 days giving the best response. They also say larger phase 3 trials are needed to confirm that it works.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was small (20 patients), had no comparison group receiving steroids alone, and randomised only the day 3 responders, so the authors state that larger phase 3 trials are needed to confirm the findings.